EP1352072A4 - Formulierungen für die zuführung von nukleinsäuren - Google Patents

Formulierungen für die zuführung von nukleinsäuren

Info

Publication number
EP1352072A4
EP1352072A4 EP02713428A EP02713428A EP1352072A4 EP 1352072 A4 EP1352072 A4 EP 1352072A4 EP 02713428 A EP02713428 A EP 02713428A EP 02713428 A EP02713428 A EP 02713428A EP 1352072 A4 EP1352072 A4 EP 1352072A4
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
acid delivery
delivery formulations
formulations
nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02713428A
Other languages
English (en)
French (fr)
Other versions
EP1352072A2 (de
Inventor
Shikha P Barman
Krishnendu Roy
Mary Lynne Hedley
Daqing Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MGI Pharma Biologics Inc
Original Assignee
Zycos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zycos Inc filed Critical Zycos Inc
Publication of EP1352072A2 publication Critical patent/EP1352072A2/de
Publication of EP1352072A4 publication Critical patent/EP1352072A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP02713428A 2001-01-17 2002-01-17 Formulierungen für die zuführung von nukleinsäuren Withdrawn EP1352072A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26221901P 2001-01-17 2001-01-17
US262219P 2001-01-17
US27025601P 2001-02-20 2001-02-20
US270256P 2001-02-20
US30048401P 2001-06-22 2001-06-22
US300484P 2001-06-22
PCT/US2002/001379 WO2002057424A2 (en) 2001-01-17 2002-01-17 Nucleic acid delivery formulations

Publications (2)

Publication Number Publication Date
EP1352072A2 EP1352072A2 (de) 2003-10-15
EP1352072A4 true EP1352072A4 (de) 2004-09-01

Family

ID=27401491

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02713428A Withdrawn EP1352072A4 (de) 2001-01-17 2002-01-17 Formulierungen für die zuführung von nukleinsäuren

Country Status (4)

Country Link
EP (1) EP1352072A4 (de)
JP (1) JP2004521109A (de)
CA (1) CA2435287A1 (de)
WO (1) WO2002057424A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
WO2003070905A2 (en) * 2002-02-15 2003-08-28 Zycos, Inc. Electroporation methods for introducing bioactive agents into cells
PT1534340E (pt) 2002-09-06 2012-03-13 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
CN101415443A (zh) * 2003-10-23 2009-04-22 阿尔扎公司 涂覆微喷射体的稳定dna组合物
US20080095822A1 (en) * 2004-11-16 2008-04-24 Universite De Liege Active Substance Delivery System Comprising A Hydrogel Atrix And Microcarriers
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
WO2012144560A1 (ja) * 2011-04-19 2012-10-26 国立大学法人京都大学 自己ゲル化核酸
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US11452759B2 (en) * 2015-01-19 2022-09-27 Technion Research & Development Foundation Limited Ubiquitin ligase KPC1 promotes processing of P105 NF-κB1 to p50, eliciting strong tumor suppression
KR101637883B1 (ko) * 2015-09-30 2016-07-21 선바이오(주) 폴리에틸렌글리콜 수화젤 주사제
KR101666792B1 (ko) * 2016-02-05 2016-10-17 주식회사 파마리서치프로덕트 핵산 및 키토산을 포함하는 온도감응성 하이드로겔 조성물
CN111333878B (zh) * 2019-05-23 2020-11-10 吾奇生物医疗科技(镇江)有限公司 一种双交联壳聚糖水凝胶及其制备方法和应用
CN109134855B (zh) * 2018-07-23 2021-03-23 安徽大学 一种酸敏感的聚酰胺胺的阳离子聚合物poeamam及其制备方法和应用
CN113683780B (zh) * 2021-09-15 2022-07-05 广州医科大学 具有穿膜活性和细胞核定位功能的抗血清、低细胞毒性的聚氨基酸类基因递送载体材料

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987029A1 (de) * 1998-08-28 2000-03-22 Transgene S.A. Verwendung eines kationischen Polymer zur Herstellung von Nukleinsäure-Komplexe und verwandte Zusammensetzungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3940316A1 (de) * 1989-12-06 1991-06-13 Bollig & Kemper Waessrige dispersionen von vernetzten polymermikroteilchen
US5534259A (en) * 1993-07-08 1996-07-09 Liposome Technology, Inc. Polymer compound and coated particle composition
US5972707A (en) * 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
US6132765A (en) * 1996-04-12 2000-10-17 Uroteq Inc. Drug delivery via therapeutic hydrogels
EP0932390A1 (de) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutische liposomenzusammensetzung und verfahren
ES2198057T3 (es) * 1997-06-30 2004-01-16 Ciba Specialty Chemicals Water Treatments Limited Materiales polimericos y su utilizacion.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0987029A1 (de) * 1998-08-28 2000-03-22 Transgene S.A. Verwendung eines kationischen Polymer zur Herstellung von Nukleinsäure-Komplexe und verwandte Zusammensetzungen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KABANOV A V ET AL: "DNA COMPLEXES WITH POLYCATIONS FOR THE DELIVERY OF GENETIC MATERIALINTO CELLS", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 6, no. 1, 1995, pages 7 - 20, XP000494803, ISSN: 1043-1802 *
MATTSON G ET AL: "A practical approach to crosslinking.", MOLECULAR BIOLOGY REPORTS. APR 1993, vol. 17, no. 3, April 1993 (1993-04-01), pages 167 - 183, XP009033258, ISSN: 0301-4851 *

Also Published As

Publication number Publication date
EP1352072A2 (de) 2003-10-15
WO2002057424A3 (en) 2002-10-03
JP2004521109A (ja) 2004-07-15
CA2435287A1 (en) 2002-07-25
WO2002057424A2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
AU2002303243A1 (en) Imaging nucleic acid delivery
GB0319041D0 (en) Pharmaceutical Formulations
EP1404860A4 (de) Zuführsystem für nukleinsäuren
IL162042A0 (en) Liposome composition for delivery of nucleic acid
EP1434601A4 (de) Liposom-verkapselte insulinformulierungen
HUP0302847A3 (en) Pharmaceutical formulation comprising bicalutamide
IL159532A0 (en) Enteral formulations
GB0012997D0 (en) Gene delivery
EP1391209A4 (de) Proteinzubereitung
EP1352072A4 (de) Formulierungen für die zuführung von nukleinsäuren
GB0103638D0 (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
AU2002365188A8 (en) Nucleic acid delivery and expression
IL161902A0 (en) Pharmaceutical formulation comprising bicalutamide
GB2380129B (en) Pharmaceutical formulations
GB0105560D0 (en) Pharmaceutical formulations
EP1446488A4 (de) Reguliertes nukleinsäureexpressionssystem
AU2002366435A8 (en) Nucleic acid amplification
IL158172A0 (en) Pharmaceutical compositions containing (-)-hydroxycitric acid
GB0124455D0 (en) Pharmaceutical formulations
GB0112585D0 (en) Nucleic acid delivery
GB0110525D0 (en) Nucleic acid delivery
AU2002347346A8 (en) Dna vaccine
EP1387892A4 (de) Verbindungen zur zuführung von genen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040719

17Q First examination report despatched

Effective date: 20070126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070807